IS2473B - Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess - Google Patents

Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess

Info

Publication number
IS2473B
IS2473B IS7825A IS7825A IS2473B IS 2473 B IS2473 B IS 2473B IS 7825 A IS7825 A IS 7825A IS 7825 A IS7825 A IS 7825A IS 2473 B IS2473 B IS 2473B
Authority
IS
Iceland
Prior art keywords
pharmaceutically
salt
methylpyrazin
oxadiazol
sulfonamide
Prior art date
Application number
IS7825A
Other languages
English (en)
Other versions
IS7825A (is
Inventor
Thomas Boyle Francis
Owen Curwen Jon
James Gallagher Neil
Joy Hancox Ursula
Mark Hughes Andrew
Johnstone Donna
Tomiko Taylor Sian
William Tonge David
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7825A publication Critical patent/IS7825A/is
Publication of IS2473B publication Critical patent/IS2473B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS7825A 2002-10-12 2005-04-26 Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess IS2473B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223854.1A GB0223854D0 (en) 2002-10-12 2002-10-12 Therapeutic treatment
PCT/GB2003/004347 WO2004035057A1 (en) 2002-10-12 2003-10-07 Therapeutic treatment

Publications (2)

Publication Number Publication Date
IS7825A IS7825A (is) 2005-04-26
IS2473B true IS2473B (is) 2008-12-15

Family

ID=9945876

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7825A IS2473B (is) 2002-10-12 2005-04-26 Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess

Country Status (29)

Country Link
US (1) US20060122180A1 (is)
EP (1) EP1553950B1 (is)
JP (1) JP2006510605A (is)
KR (1) KR20050056238A (is)
CN (1) CN100342853C (is)
AR (1) AR041595A1 (is)
AT (1) ATE369136T1 (is)
AU (1) AU2003269259B2 (is)
BR (1) BR0315140A (is)
CA (1) CA2501959A1 (is)
CY (1) CY1107605T1 (is)
DE (1) DE60315490T2 (is)
DK (1) DK1553950T3 (is)
ES (1) ES2289316T3 (is)
GB (1) GB0223854D0 (is)
IS (1) IS2473B (is)
MX (1) MXPA05003808A (is)
MY (1) MY135441A (is)
NO (1) NO20051658L (is)
NZ (1) NZ539137A (is)
PL (1) PL375584A1 (is)
PT (1) PT1553950E (is)
RU (1) RU2005114487A (is)
SA (1) SA04240502B1 (is)
TW (1) TW200412971A (is)
UA (1) UA82492C2 (is)
UY (1) UY28017A1 (is)
WO (1) WO2004035057A1 (is)
ZA (1) ZA200502874B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
KR101019264B1 (ko) * 2006-03-13 2011-03-07 엔싸이시브 파마슈티칼즈 인코퍼레이티드 Ｎ-(4-클로로-3-메틸-5-이속사졸릴)-2-[2-메틸-4,5-(메틸렌디옥시)페닐아세틸]티오펜-3-술폰아미드 나트륨 염의 다형체
EP2433620A1 (en) * 2007-10-12 2012-03-28 AstraZeneca AB Zibotentan Composition
HRP20150890T1 (hr) * 2009-08-10 2015-09-25 Board Of Regents, The University Of Texas System Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom
EA202091630A1 (ru) 2018-01-12 2020-12-04 Инб Терапьютикс, Инк. Дейтерированные соединения, композиции и способы для лечения раков, связанных с активацией etbr
US20220265628A1 (en) * 2019-07-17 2022-08-25 Enb Therapeutics, Inc. Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
TW202317555A (zh) * 2021-06-22 2023-05-01 日商亞克醫藥股份有限公司 化合物、內皮素a受體拮抗劑及醫藥組合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
CN1298396A (zh) * 1998-04-29 2001-06-06 Osi药物公司 N－(乙炔苯氨基)－6,7－双(2－甲氧基乙氧基)－4－喹唑啉胺甲磺酸盐无水物和一水合物
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen

Also Published As

Publication number Publication date
ATE369136T1 (de) 2007-08-15
DK1553950T3 (da) 2007-10-15
IS7825A (is) 2005-04-26
SA04240502B1 (ar) 2008-09-14
CN1703224A (zh) 2005-11-30
AU2003269259A1 (en) 2004-05-04
ES2289316T3 (es) 2008-02-01
DE60315490D1 (de) 2007-09-20
CY1107605T1 (el) 2013-03-13
EP1553950A1 (en) 2005-07-20
MXPA05003808A (es) 2005-06-08
AR041595A1 (es) 2005-05-26
MY135441A (en) 2008-04-30
JP2006510605A (ja) 2006-03-30
HK1078784A1 (en) 2006-03-24
US20060122180A1 (en) 2006-06-08
EP1553950B1 (en) 2007-08-08
GB0223854D0 (en) 2002-11-20
UY28017A1 (es) 2004-04-30
BR0315140A (pt) 2005-08-16
UA82492C2 (uk) 2008-04-25
NO20051658L (no) 2005-05-06
AU2003269259B2 (en) 2007-03-15
DE60315490T2 (de) 2008-05-08
PT1553950E (pt) 2007-09-26
WO2004035057A1 (en) 2004-04-29
KR20050056238A (ko) 2005-06-14
NZ539137A (en) 2008-01-31
CA2501959A1 (en) 2004-04-29
ZA200502874B (en) 2006-02-22
RU2005114487A (ru) 2006-02-10
CN100342853C (zh) 2007-10-17
PL375584A1 (en) 2005-11-28
TW200412971A (en) 2004-08-01

Similar Documents

Publication Publication Date Title
ZA200409814B (en) 3-Z-(1-(4-(N-((4-methyl-piperazin-1-YL)-methylcarbnonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene)-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition.
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
IS7840A (is) 3-(3,5-díoxó-4,5-díhýdró-3H-(1,2,4)tríasín-2-ýl)-bensamíð afleiður sem P2X7-hindrar til notkunar í meðferð á bólguvaldandi sjúkdómum
PL1663236T3 (pl) Kombinacja zawierająca N-(3-metoksy-5-metylopirazyn-2-ylo)-2-(4-(1,3,4-oksadiazol-2-ilo)fenylo)pirydyno-3-sulfonamid i bifosfonian
IS6913A (is) 3-(4-amídópýrról-2-ýlmetlíden)-2-indólínon afleiður sem prótein kínasa hindrar
DK1697378T3 (da) Indoler, 1H-indazoler, 1,2-benzisoxazoler og 1,2-benzisothiazoler og fremstilling og anvendelser deraf
IS8216A (is) 4-(metýl súlfónýl amínó) fenýl hliðstæður sem vaníllóíð mótlyf, og sem sýna frábæra kvalastillandi virkni, og lyfjafræðilegar samsetningar, sem innihalda þær
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DK1581518T3 (da) Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
IL188483A0 (en) Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
FR2846545B1 (fr) Implant d'osteosynthese intramedullaire
IS2473B (is) Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess
DE60315762D1 (de) Titanoxid-Dispersionszusammensetzung
NO20043580D0 (no) Quinazolinonderivater og deres bruk som CB agonister
EE200400043A (et) Uudsed heterotsüklilised ühendid kui selektiivsedbakteriaalsed DHFR inhibiitorid ning nende kasutamine
ATE356143T1 (de) Antibiotikum 107891, dessen faktoren a1 und a2, pharmazeutisch unbedenkliche salze und zusammensetzungen, und anwendung davon
PT1545710E (pt) Utilização de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil) piridino-3-sulfonamida no tratamento de cancro
IL178785A0 (en) Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
AU2003272007A1 (en) Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
DK1641787T3 (da) Substituerede diketopiperaziner og deres anvendelse som oxytocinantagonister
NO20030998L (no) Arylpiperazinderivater og deres anvendelse som psykotropiske midler
DK1532141T3 (da) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv
DK1648897T3 (da) N-3-3-substituerede-pyrazolo[1,5-A]pyrimidin-7YL)phenyl]-sulfonamider og sammensætninger og dermed relaterede fremgangsmåder
DE60217870D1 (de) Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze